Daratumumab, Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated Efficacy Analysis of CASTOR

Conference Correspondent  - Conference Correspondent, ASH

Daratumumab is a human CD38 IgGκ monoclonal antibody that demonstrated significant activity and a manageable safety profile in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (RRMM).

Investigators of the CASTOR trial, led by Chanan-Khan, examined subgroups to compare the efficacy of daratumumab added to bortezomib/dexamethasone (DVd) in the bortezomib-naive and bortezomib-experienced patient populations. They also evaluated the efficacy of DVd versus Vd in patients who were refractory to lenalidomide as their last prior line of therapy. Median follow-up was 13.0 months. The following outcomes were observed by subset:

  • Bortezomib-naive patients (n = 172): Median progression-free survival (PFS) was not reached with DVd, and was 7.5 months with Vd. The estimated 12-month PFS was 74.6% versus 32.3%, respectively.
  • Bortezomib-exposed patients (n = 326): Median PFS was 12.4 months with DVd compared with 6.7 months with Vd. Estimated 12-month PFS rates were 51.3% and 15.2%, respectively.
  • Lenalidomide-refractory patients (n = 105): Median PFS was 9.3 months with DVd versus 4.4 months with Vd.

Objective response rates, including rates of very good partial response or better, were significantly improved by DVd in all subsets.

These analyses confirm that the addition of daratumumab to Vd significantly improves outcomes for patients with RRMM, regardless of prior treatment with bortezomib. Importantly, the benefit of DVd versus Vd was maintained in patients who were refractory to lenalidomide as the last prior line of therapy.

Chanan-Khan AA, et al. 2016 ASH. Abstract 3313.

Related Items
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Subcutaneous Romiplostim Increased Platelet Response in Children with ITP
Conference Correspondent  published on December 27, 2017 in ASH
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Last modified: December 5, 2017